ATRC

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Atricure Inc

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator ® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip ® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.
CEO
Employees
750
Headquarters

News

Coinbase To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Friday
Feb 16, 2024 13:30pm

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Piper Sandler raised the price target for Toast, Inc. (NYSE: TOST ) from $18 to $20. Piper Sandler analyst Clarke Jeffries maintained a Neutral rating. Toast shares fell 4.7% to close at $19.20 on Thursday. See how other analysts view this stock . Canaccord Genuity boosted Coinbase Global, Inc. (NASDAQ: COIN ) price target from $140 to $240. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Coinbase shares gained 3.3% to close at $165.67 on Thursday. See how other analysts view this stock. Needham boosted the price target for AtriCure, Inc. (NASDAQ: ATRC ) from $44 to $46. Needham analyst Mike Matson maintained a Buy rating. AtriCure shares rose 5.1% to close at $34.21 on … Full story available on Benzinga.com


Source:Benzinga
Earnings call: AtriCure reports robust growth, eyes new product launches
Feb 16, 2024 12:54pm

https://www.investing.com/news/stock-market-news/earnings-call-atricure-reports-robust-growth-eyes-new-product-launches-93CH-3306283


Source:Investing.com
AtriCure, Inc. (ATRC) Q4 2023 Earnings Call Transcript
Feb 16, 2024 03:30am

No summary available.


Source:Seeking Alpha
AtriCure Non-GAAP EPS of -$0.21 beats by $0.02, revenue of $106.5M beats by $2.34M
Feb 15, 2024 21:07pm

No summary available.


Source:Seeking Alpha
AtriCure''s Earnings: A Preview
Feb 14, 2024 15:01pm

AtriCure (NASDAQ: ATRC ) is set to give its latest quarterly earnings report on Thursday, 2024-02-15. Here''s what investors need to know before the announcement. Analysts estimate that AtriCure will report an earnings per share (EPS) of $-0.23. AtriCure bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next … Full story available on Benzinga.com


Source:Benzinga
Allspring Global Investments Holdings LLC Raises Stake in AtriCure, Inc. (NASDAQ:ATRC)
Feb 03, 2024 10:40am

… the period. Allspring Global Investments Holdings LLC’s holdings in … (SEC). Several other institutional investors and hedge funds have also … funds and other institutional investors own 94.30% of … .50. Want More Great Investing Ideas? View Our Latest Analysis …


Source:EIN News Investing
AtriCure stock jumps on upbeat 2024 revenue outlook
Jan 08, 2024 17:01pm

No summary available.


Source:Seeking Alpha
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2023, Provides Financial Outlook for 2024
Jan 08, 2024 13:00pm

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced preliminary financial results for the fourth quarter and full year 2023 and provided 2024 financial guidance. Preliminary, unaudited revenue for fourth quarter 2023 is expected to be $106.5


Source:Wallstreet:Online